Á¦24Â÷ ´ëÇѼҾƽÉÀåÇÐȸ Ãá°è Çмú´ëȸ : 2024-06-15
±³À°ÀÏÀÚ : 2024-06-15
±³À°Àå¼Ò : Ä¥°î°æºÏ´ëÇб³º´¿ø ´ë°´ç
±³À°ÁÖÁ¦ : Á¦24Â÷ ´ëÇѼҾƽÉÀåÇÐȸ Ãá°è Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѼҾƽÉÀåÇÐȸ
´ã´çÀÚ : ÁøÇü¼·
¿¬¶ôó : 02-6952-0250
À̸ÞÀÏ : pediheart@pediheart.or.kr
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú, ÈäºÎ¿Ü°ú
Âü¼®¿¹»óÀÎ : 170¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Àü¹®ÀÇ (80,000) Àü°øÀÇ, °£È£»ç, ±â»ç, ±âŸ (50,000) Çлý(¹«·á)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 08:30~08:45 ¼Ò¾Æ½ÉÀå³»°ú ÀÇ»çÀÇ »î °íÈÆ(¾ç»êºÎ»ê´ëº´¿ø)
±âŸ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 08:45~09:00 ¼Ò¾Æ½ÉÀå¿Ü°ú ÀÇ»çÀÇ »î °ûÀç°Ç(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 09:00~09:15 ¼Ò¾Æ½ÉÀå³»°ú ¼ö°¡°³¼± ³ë·Â Çѹ̿µ(°æÈñ´ëº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 09:15~09:30 ¼Ò¾Æ½ÉÀå¿Ü°ú ¼ö°¡°³¼± ³ë·Â ¹Úõ¼ö(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 09:30~09:45 ȯ¿ìȸ¿¡¼ º¸´Â ¼Ò¾Æ½ÉÀåÄ¡·á ¹ßÀüÁ¦¾È ¾È»óÈ£(Çѱ¹¼±Ãµ½ÉÀ庴ȯ¿ìȸ)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 09:45~10:15 ÀÇ·á¼Ò¼Û ÃֽŠ°æÇâ ³²±Ã°æ(¼¿ï´ëº´¿ø)
Åä·Ð 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 10:15~10:40 Discussion ()
ÈÞ½Ä 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 10:40~11:00 Coffee break ()
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 11:00~11:15 Chest X-ray and EKG ³ªÀçÀ±(ÇѾç´ëº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 11:15~11:30 Echocardiography ±è¹ÌÁø(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 11:30~11:45 ICU care after cardiac procedure ÀÌ¿ÁÁ¤(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 11:45~12:00 Intervention for congenital heart disease ±èÁ¤À±(ºÎõ¼¼Á¾º´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 12:00~12:15 Surgery for congenital heart disease ÃÖÀº¼®(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 12:15~12:45 ChatGPT ÀÚ·á¼öÁý ¹× ³í¹®ÀÛ¼º ¾È»óÁø(ÀÎÁ¦´ëÇб³)
Åä·Ð 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 12:45~13:00 Discussion ()
½Ä»ç 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 13:00~14:00 ÃÑȸ ¹× Á¡½É ()
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 14:30~14:40 (±¸¿¬)Phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostate mesylate in patients with Protein-losing enteropathy after Fontan operation ¹Ú¿ì¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 14:40~14:50 (±¸¿¬)Epidemiology and outcome of Pediatric patients with Inherited arrhythmias in Korean multicenter study ¹ÝÁöÀº(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 14:50~15:00 (±¸¿¬)Clinical Characteristics and Outcomes of Pediatric Patients with Long QT syndrome: A Korean Multicenter Cohort Study ¼Û¹Ì°æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:00~15:10 (±¸¿¬)Predictive value of soluble ST2 in pediatric cardiac intensive care unit º¯ÁöÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:10~15:20 (±¸¿¬)Long-term Fate of Systemic Right Ventricle in Bi-ventricle and Single Ventricle ±èÂùÇü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:20~15:30 (±¸¿¬)Changes in Korea ¹Ú¿µÈ¯(Çѱ¹½ÉÀåÀç´Ü)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:30~15:40 (±¸¿¬)Comprehensive management of tetralogy of Fallot with pulmonary atresia with a ductus-dependent pulmonary circulation ±èÇüÅÂ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:40~15:50 (±¸¿¬)The impact of inappropriate steroid exposure before the diagnosis of Kawasaki disease Á¤Âù¿µ(°æ»óÀÇ´ë)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 15:50~16:00 (±¸¿¬)Urgent Cardiac Catheterization in Seriously-Ill Patients with Congenital Heart Disease: Early and Intermediate-Term Results Àå±â¿µ(°í·ÁÀÇ´ë)
ÈÞ½Ä 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 16:00~16:20 Coffee break ()
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 16:20~16:35 Mitral regurgitation in normal connection Á¶ÈÁø(Àü³²´ëº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 16:35~16:50 AV valve regurgitation in single ventricle ¹éÀç¼÷(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 16:50~17:05 Tricuspid regurgitation in ccTGA ÀÌ»óÀ±(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 17:05~17:20 My technique in systemic AV valve treatment (SMC) ¾çÁöÇõ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 17:20~17:35 My technique in systemic AV valve treatment (SNUCH) ±è¿õÇÑ(¼¿ï´ëº´¿ø)
Åä·Ð 06¿ù 15ÀÏ ÁöÇÏ 1Ãþ ´ë°´ç 17:35~17:50 Discussion ()